ArticleFrontiers in immunology2026

CD161 serves as a prognostic biomarker and predicts immunotherapy response in head and neck squamous cell carcinoma.

Shuai Mei et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.